03/08/2026
Antibody-drug conjugates (ADCs) are transforming cancer care. As their use expands, so does the need for ECPs to recognize and manage the ocular toxicities that come with them.
The latest supplement from Axiom Ophthalmic, featured in COOKIE 24, brings together six leading experts to explore exactly that.
Across three in-depth articles, the faculty covers:
Antibody Drug Conjugates and the Cornea
Dr. Mile Brujic and Dr. Asim Farooq break down the signs and symptoms of ADC-related corneal toxicity, from pseudomicrocysts and refractive shifts to what slit lamp findings actually look like in practice.
Managing Ocular Side Effects Associated with ADCs
Dr. Aaron Gold and Dr. Joann Kang walk through evidence-based prevention, monitoring protocols and the importance of close collaboration between ECPs and oncology teams.
Recognition, Grading and Management of Ocular Toxicities
Dr. Kaleb Abbott and Dr. Neel Pasricha review grading scales, prophylactic strategies and the role of interdisciplinary care in keeping patients on life-saving therapies.
As ADCs move from salvage therapies toward earlier lines of treatment, ECPs are increasingly likely to encounter these patients in everyday practice. This supplement offers practical, clinically relevant guidance to help prepare for that reality.
Read the full Axiom Supplement: https://issuu.com/mediamice/docs/cookie_24_supplement/1?fr=sODU5NDkyMTU1MDE
This content is intended exclusively for healthcare professionals and eye care practitioners. It is not intended for the general public. Products or therapies discussed may not be registered or approved in all jurisdictions, including Singapore.
Axiom Ophthalmic
COOKIE Issue 24 Supplement: Managing Ocular Side Effects Associated with Antibody Drug Conjugate Cancer Therapies